[go: up one dir, main page]

AR006202A1 - Usos de antagonista ige para preparar un medicamento util para el tratamiento de las enfermedades alergicas y composiciones que los contiene - Google Patents

Usos de antagonista ige para preparar un medicamento util para el tratamiento de las enfermedades alergicas y composiciones que los contiene

Info

Publication number
AR006202A1
AR006202A1 ARP970100986A ARP970100986A AR006202A1 AR 006202 A1 AR006202 A1 AR 006202A1 AR P970100986 A ARP970100986 A AR P970100986A AR P970100986 A ARP970100986 A AR P970100986A AR 006202 A1 AR006202 A1 AR 006202A1
Authority
AR
Argentina
Prior art keywords
prepare
treatment
ige
ige antagonist
compositions containing
Prior art date
Application number
ARP970100986A
Other languages
English (en)
Original Assignee
Univ Johns Hopkins
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins, Genentech Inc filed Critical Univ Johns Hopkins
Publication of AR006202A1 publication Critical patent/AR006202A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Usos y composiciones de antagonista IgE para preparar un medicamento útil para el tratamiento de una enfermedad alérgica caracterizado por una cantidadefectiva de dicho antagonista IgE, que es administrado como: (a) una dosis de carga durante unperíodo de al menos alrededor de 14 días suficientes parareducir el nivel promedio de IgE libre en suero del paciente hasta un nivel no mayor de alrededor de 50ng/ml al final del período de carga; seguido por (b)una dosis de mantenimiento entrealre dedor de 8x10(5) hasta 2.4x10(3) mg/kg/semana del antagonista IgE para cada IU/ml línea de base IgE libre en elsuero del paciente.
ARP970100986A 1996-03-12 1997-03-12 Usos de antagonista ige para preparar un medicamento util para el tratamiento de las enfermedades alergicas y composiciones que los contiene AR006202A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61422096A 1996-03-12 1996-03-12

Publications (1)

Publication Number Publication Date
AR006202A1 true AR006202A1 (es) 1999-08-11

Family

ID=24460327

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970100986A AR006202A1 (es) 1996-03-12 1997-03-12 Usos de antagonista ige para preparar un medicamento util para el tratamiento de las enfermedades alergicas y composiciones que los contiene

Country Status (8)

Country Link
EP (1) EP0904108A1 (es)
JP (1) JP2001505181A (es)
AR (1) AR006202A1 (es)
AU (1) AU726143B2 (es)
CA (1) CA2246427A1 (es)
IL (1) IL126113A0 (es)
WO (1) WO1997033616A1 (es)
ZA (1) ZA971607B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US7393529B2 (en) 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
WO2001040264A2 (en) * 1999-12-06 2001-06-07 Panacea Pharmaceuticals, Llc. Peptide antigens
GB0016441D0 (en) 2000-07-04 2000-08-23 Pharmagene Lab Limited Therapeutic method
US6787524B2 (en) 2000-09-22 2004-09-07 Tanox, Inc. CpG oligonucleotides and related compounds for enhancing ADCC induced by anti-IgE antibodies
US20040146502A1 (en) * 2001-05-03 2004-07-29 Elisabeth Latour Use of organic compounds
GB201610198D0 (en) * 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
CN114028569B (zh) * 2021-12-20 2023-04-28 中国医学科学院基础医学研究所 免疫球蛋白IgE在诊断和/或治疗高血压中的用途
CN114504644B (zh) * 2021-12-24 2024-02-13 北京大学第一医院 抗IgE抗体在用于治疗腺样体肥大中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5449760A (en) * 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US4940715A (en) * 1988-05-17 1990-07-10 Kissei Pharmaceutical Co., Ltd. 5H-pyrazolo[4,3-A] quinolizin-5-one compounds exhibiting therapeutic activities
JP3156237B2 (ja) * 1991-12-24 2001-04-16 雪印乳業株式会社 抗ヒトIgE モノクローナル抗体

Also Published As

Publication number Publication date
JP2001505181A (ja) 2001-04-17
EP0904108A1 (en) 1999-03-31
ZA971607B (en) 1998-08-25
WO1997033616A1 (en) 1997-09-18
AU1987597A (en) 1997-10-01
AU726143B2 (en) 2000-11-02
IL126113A0 (en) 1999-05-09
CA2246427A1 (en) 1997-09-18

Similar Documents

Publication Publication Date Title
ATE138562T1 (de) Transmukosale dosisform
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
KR101900520B1 (ko) 복합 조성물
PT88985A (pt) Processo para a preparacao de composicoes farmaceuticas nasais e ou oftalmicas contendo azelastina
ES2171469T3 (es) Composicion administrada por via nasal y preparacion que la contiene.
EP1064000A4 (en) VITAMIN D AND ITS ANALOGS FOR THE TREATMENT OF TUMORS AND OTHER HYPERPROLIFERATION DISORDERS
ATE185268T1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
ES2182899T3 (es) Formulacion farmaceutica para la administracion subcutanea, intramuscular o intradermica de factor viii.
ATE94393T1 (de) Dosisform zur oralen verabreichung des hypoglykaemischen glipizids.
DK0416950T3 (da) Medikamenter
MX173567B (es) Procedimiento para preparar una composicion farmaceutica y composicion farmaceutica para mejorar los sintomas de enfermedad inducida por vih o reducir la transcripcion y proliferacion del vih
AU1935788A (en) A process for producing an administration and/or dosage form for medically active ingredients of drugs
AR006202A1 (es) Usos de antagonista ige para preparar un medicamento util para el tratamiento de las enfermedades alergicas y composiciones que los contiene
RU95101385A (ru) Продукты, содержащие g-csf и tnf связующие протеина
ES2139842T3 (es) Uso de la melatonina para tratar a pacientes que sufren drogodependencia.
DK0412554T3 (da) Sustained-release-præparat til administration i hjernen
ES2119748T3 (es) Composicion farmaceutica que contiene un farmaco ligeramente soluble en agua.
KR890006227A (ko) 페놀-함유 진해성 액체 조성물
ES2115571T3 (es) Uso de polisulfato de pentosana para la resolucion de cicatrices en enfermedades vasculares progresivas cronicas.
JPS6360940A (ja) 白内障の予防または治療剤
AR002727A1 (es) El uso de ridogrel para la fabricacion de un medicamento util para el tratamiento de enfermedades digestivas inflamatorias, una composicionfarmaceutica que comprende ridogrel y un procedimiento para preparar dicha composicion.
ES2038847T3 (es) Proceso para la preparacion de una composicion farmacutica conteniendo zidovudine e inosiplex para el tratamiento del sida y sindromes afines.
ES2211594T3 (es) Medicamentos que contienen acido pantotenico para el tratamiento de enfermedades inflamatorias de las articulaciones.
AR034036A1 (es) Inhibidor de aromatasa en una dosis unica para tratar la infertilidad
EP0402208B1 (fr) Association de vitamine A à dose physiologique et de différents principes actifs ayant une activité thérapeutique